ESGPHARM
DEAD

Serial Number

90833462

Owner

G+FLAS Life Sciences

Attorney

Diane J. Mason

Filing Date

Jul 16, 2021

Add to watchlist:

No watchlists yet
View on USPTO

ESGPHARM Trademark

Serial Number: 90833462

ESGPHARM is a trademark filed by G+FLAS Life Sciences on July 16, 2021. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

G+FLAS Life Sciences (6 trademarks)

Seoul 08790 , KR

Entity Type: 03

Trademark Details

Filing Date

July 16, 2021

Registration Date

Not Registered

Goods & Services

Custom manufacture of pharmaceuticals; custom manufacturing services in the nature of processing of pharmaceutical preparations; custom manufacturing services in the nature of processing of medicinal materials; custom manufacture of biopharmaceuticals; treatment of biopharmaceutical materials; processing of biopharmaceutical materials for others; custom manufacturing services in the nature of processing of biopharmaceutical materials for others; preservation of pharmaceuticals; custom manufacturing services in the nature of processing of medical products; processing of plant material; processing of plant extracts in the nature of separation of extractants; processing of plants to obtain oils from plant material; processing of biomass; prototype fabrication of new products for others; custom manufacturing services in the nature of processing of plant growth promoting preparations; conversion of targeted substrates into targeted chemical preparations by treatment with enzyme systems; custom manufacture of pharmaceuticals using biological organisms in the manufacturing process; custom manufacturing services in the nature of processing of pharmaceutical preparations using biological organisms; custom manufacture of machines and tools for compressing and compacting powders and granules

Consultancy and information services relating to pharmaceutical products; advisory services relating to pharmaceutical products; medical consultancy relating to pharmaceutical and medical products; advisory services relating to pharmaceuticals; providing consultancy and information services relating to biopharmaceutical products; pharmaceutical advice; consultancy and information services provided via the Internet relating to pharmaceutical products; cultivation of plants for use in pharmaceuticals for others; farming services in the field of plants used for pharmaceuticals; cultivation of host plants for plant-based biopharmaceutical production for others; plant seed services, namely, providing data, information and analysis in the field of seed performance for medical purposes; information services relating to flora used in pharmaceuticals and medical treatments; plant nursery services; cultivation of plants for use in the development of biopharmaceuticals for others; provision of gene therapy for medical treatment purposes; provision of genetic information for medical treatment purposes; analysis of human biodata for medical purposes; DNA analysis for medical purposes; genetic testing for medical purposes

Pharmaceutical research and development; pharmaceutical drug development services; inspection of pharmaceuticals; consultancy in the fields of pharmaceutical research and development; analysis and evaluation of medical product development; research relating to medicines; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; research and development in the field of plant-based biopharmaceutical production; development of pharmaceutical preparations and medicines; medical research in the field of crude drugs; microbial culture trials; protein analysis for scientific research purposes; industrial analysis and research services in the field of protein analysis; genetic engineering services relating to plants; scientific research relating to genetics of plants; providing laboratory research services in the field of gene expression, namely, cancer biology; laboratory services relating to the production of monoclonal antibodies; genetic engineering services relating to plants for pharmaceuticals; scientific research relating to plant breeding for pharmaceuticals

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Mar 21, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Mar 21, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 21, 2023 ABN2
ASSIGNED TO EXAMINER
Mar 20, 2023 DOCK
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 14, 2022 GNRN
NON-FINAL ACTION E-MAILED
Apr 14, 2022 GNRT
NON-FINAL ACTION WRITTEN
Apr 14, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 6, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 20, 2021 NWOS
NEW APPLICATION ENTERED
Jul 20, 2021 NWAP